articleThe LancetMar 1, 2026HYBRID OA

Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial

DJDavid J ThomsonJMJames M. PriceMAMatthew A. TylerMBMatthew BeasleyJLJim Lester

Cancer Research UK · Manchester University NHS Foundation Trust · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

The clinical benefits of intensity-modulated proton therapy (IMPT) compared with intensity-modulated radiation therapy (IMRT) for patients with oropharyngeal squamous cell carcinoma remain uncertain with respect to treatment-related effects on physical function and quality of life. We aimed to compare late functional, patient-reported, disease control, and survival outcomes between IMPT and IMRT.

Methods

, every 3 weeks). Co-primary endpoints at 12 months were gastrostomy-tube dependence (use of feeding tube for nutrition) or severe weight loss (≥20% from baseline) and University of Washington quality of life (UW-QoL) mean physical composite score for saliva, taste, chewing, swallowing, speech and appearance. The study was registered with the ISRCTN registry, ISRCTN16424014; recruitment is complete and follow-up is ongoing.

Citation impact

4
total citations
FWCI
108.50
Percentile
100%
References
26
Too recent for citation history.

Authors

26

Topics & keywords

Keywords
  • Cancer
  • Randomized controlled trial
  • Beam (structure)
  • Phase (matter)
  • Proton
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding